|
Disappointing drug trials pull Alcon stock down 11 percent.
Publication: The Dallas Morning News (Dallas, Texas) (via Knight-Ridder/Tribune Business News) Publication Date: 15-OCT-04 |
|
|
|
How to access the full article: Free access to all articles is available courtesy of your local library. To access the full article click the "See the full article" button below. You will need your US library barcode or password.
|
|
|
COPYRIGHT 2004 The Dallas Morning News
Byline: Roger Yu
Oct. 15--Shares of Alcon Inc. fell 11 percent Thursday after the company revealed that a clinical test shows its much-anticipated drug for treating blindness hasn't outperformed a rival product already on the market.
In the one-year study, Alcon, a Swiss maker of eye-care products with its U.S. headquarters in Fort Worth, compared its drug, Retaane, with Novartis AG's Visudyne.
The percentage of patients who maintained vision when treated with Alcon's drug was 45...
Read the full article for free courtesy of your local library.
|
|
|
|
 |
| More Articles from The Dallas Morning News (Dallas, Texas) (via Knight-Ridder/Tribune Business News) |
Home foreclosures rise 4 percent for Dallas-Fort Worth area.
October 15, 2004
|
Plano, Texas, tests idea for lending program for downtown home buyers.
October 15, 2004
|
Nokia's profits weaken.
October 15, 2004
|
Oil prices move closer to $55.
October 15, 2004
|
North Texas retirees choose to stay in urban areas, with more options ...
October 15, 2004
|
|
Bookmark this article
Print this article
Link to this article
Email this article
Digg It!
Add to del.icio.us
RSS
